Efficacy Study Of Tofacitinib In Pediatric JIA Population
NCT02592434
·
clinicaltrials.gov ↗
PHASE3
Phase
COMPLETED
Status
225
Enrollment
INDUSTRY
Sponsor class
Conditions
Juvenile Idiopathic Arthritis
Interventions
DRUG:
CP-690,550 (tofacitinib)
OTHER:
placebo
Sponsor
Pfizer